Physician profile
Jayson D Henry
NPI 1053393827
$3,722.15
in general payments reported to CMS, 2019-2025
31 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $500 · 2021: $863 · 2022: $616 · 2023: $610 · 2024: $356 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,091.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $575.43 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $445.13 | 2019-2023 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $358.53 | 2020-2024 | Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $327.10 | 2019-2023 | Jardiance |
| Abbvie INC. | $249.05 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $241.48 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Lilly USA, LLC | $206.46 | 2019-2024 | Mounjaro, Zepbound, Trulicity |
| Astellas Pharma US INC | $190.17 | 2019-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $180.90 | 2020-2025 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $150.61 | 2019-2022 | |
| Medtronic, INC. | $112.02 | 2022-2025 | Inceptiv, Intellis Adaptivestim |
| Amarin Pharma, INC. | $86.67 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $84.03 | 2019-2023 | Spravato, Xarelto |
| Sanofi-Aventis U.S. LLC | $73.81 | 2020-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.44 | 2021-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $47.91 | 2019-2021 | |
| Abbott Laboratories | $38.57 | 2022-2024 | Eterna |
| Biogen, INC. | $36.88 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $36.32 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $30.82 | 2019 | |
| Arbor Pharmaceuticals, INC. | $25.01 | 2019 | |
| Sunovion Pharmaceuticals INC. | $23.52 | 2021 | |
| Inspire Medical Systems, INC. | $18.24 | 2025 | Inspire |
| Gilead Sciences, INC. | $18.00 | 2019 | |
| Corium, LLC | $17.85 | 2022 | |
| Eisai INC. | $17.14 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.95 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.90 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.43 | 2019 | |
| Horizon Therapeutics Plc | $11.53 | 2020 | |
| Bardy Diagnostics, INC. | $10.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayson Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.